Shares of biopharmaceutical firm Aclaris Therapeutics Inc (NASDAQ: ACRS) have made substantial gains on Tuesday after the company reported positive data from its mid-stage rheumatoid arthritis ATI-450 trial.
Aclaris’ stock price is trading over 156% higher at $15.10 per share.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
ATI-450, an investigational oral MK2 inhibitor, used to treat patients with moderate to severe rheumatoid arthritis. It was developed by Aclaris, using its proprietary KINect™ drug discovery platform.
The trial involved 19 subjects with each patient receiving either ATI-450 at 50 mg twice daily or placebo, combined with methotrexate, for 12 weeks. The trial’s primary endpoint was safety and tolerability with the secondary endpoints, including disease activity scores, and the change from baseline in high sensitivity C-reactive protein and appropriate endogenous cytokine levels.
The company said the drug demonstrated durable clinical activity over 12 weeks, was generally well-tolerated, and that data supports a new oral approach for the potential treatment of immuno-inflammatory diseases, such as rheumatoid arthritis.
The data also supports progression to a Phase 2b trial.
“We’re very pleased with these data which demonstrate that ATI-450 was generally well tolerated and showed durable clinical activity in RA over 12 weeks,” commented Dr David Gordon, Chief Medical Officer at Aclaris.
“We believe these data support our hypothesis that MK2 inhibition is an important novel target for the treatment of immuno-inflammatory diseases, such as rheumatoid arthritis, and we look forward to progressing ATI-450 to Phase 2b,” Dr Gordon added.
